TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7931862

Group type: EXPERIMENTAL
Intervention: Standard treatment plus Training and Employment Program (TEP)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Standard treatment plus TEP
Number of subjects: 250
Study: 2967089

Group type: EXPERIMENTAL
Intervention: Intravenous 7.5 mg dose of SQ 27, 519
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral 10 mg doses of fosinopril sodium (capsule and solution)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral doses of fosinopril sodium
Number of subjects: 9
Study: 31923341

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D3 (2000 IU/d)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 771
Study: 29269149

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No PRF (Control)
Number of subjects: 20
Study: 27016629

Group type: EXPERIMENTAL
Intervention: Verbal worrying
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Imagery-based worrying
Number of subjects: 125

Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 125
Study: 25944453

Group type: EXPERIMENTAL
Intervention: Rapid diagnosis and treatment of IS
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: ADOS assessment
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Symptomatic IS
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Chronic epileptic discharges in frontotemporal areas
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Non-white origin
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Early diagnosis and treatment
Number of subjects: 69
Study: 23071247

Group type: EXPERIMENTAL
Intervention: PCV plus RT
Number of subjects: 291

Group type: COMPARATOR
Intervention: RT
Number of subjects: 291
Study: 20185602

Group type: EXPERIMENTAL
Intervention: QW dosing of epoetin alfa
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Q2W dosing of epoetin alfa
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Q4W dosing of epoetin alfa
Number of subjects: 430
Study: 18237394

Group type: EXPERIMENTAL
Intervention: Vitamin A (200,000 IU) plus zinc (10 mg elemental zinc, six days a week)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 16730929

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: EPT (1 mg 17beta‐estradiol + 0.5 mg NETA)
Number of subjects: 50
Study: 14650366

Group type: EXPERIMENTAL
Intervention: nifuratel 125 mg/nystatin 50000 IU
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: nifuratel 250 mg/nystatin 100000 IU
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: nifuratel 500 mg/nystatin 200000 IU
Number of subjects: 60
Study: 10736141

Group type: EXPERIMENTAL
Intervention: Iontophoresis of a topical solution of 2% lidocaine with epinephrine 1:100,000
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2.5% lidocaine and 2.5% prilocaine (EMLA cream)
Number of subjects: 100
Study: 9124845

Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 12
Study: 1551749

Group type: EXPERIMENTAL
Intervention: Brand A of ciprofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brand B of ciprofloxacin
Number of subjects: 0
Study: 3157720

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) alone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) with cognitive therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (mean plasma levels within therapeutic window)
Number of subjects: 35
Study: 30884788

Group type: EXPERIMENTAL
Intervention: Weight loss quartile 4 (average weight loss: -10.7%)
Number of subjects: 138
Study: 29702652

Group type: EXPERIMENTAL
Intervention: Oral administration of H10407 at a dose of 105 CFU
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral administration of H10407 at a dose of 106 CFU
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as no treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immune responses measured (anti-LT toxin, CFA/I, LPS O78)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No specific intervention for asymptomatic infections
Number of subjects: 30
Study: 26395650

Group type: EXPERIMENTAL
Intervention: Positive environmental distraction intervention (minimum, light, light and animation)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Positive environmental distraction intervention
Number of subjects: 182
Study: 24659421

Group type: EXPERIMENTAL
Intervention: Physical activity intervention in preschools, including trainings, workshops, site visits, feedback, newsletters, and physical activity equipment.
Number of subjects: 8
Study: 23074170

Group type: EXPERIMENTAL
Intervention: rhGH treatment at a dose of 0.1 IU/kg/day for 14 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 25
Study: 20567613

Group type: EXPERIMENTAL
Intervention: Local anesthetic alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local anesthetic and steroids
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 120
Study: 18019914

Group type: EXPERIMENTAL
Intervention: Soft cast
Number of subjects: 117

Group type: COMPARATOR
Intervention: Rigid cast
Number of subjects: 117
Study: 16062080

Group type: EXPERIMENTAL
Intervention: Prophylactic lamivudine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Historical control (no lamivudine)
Number of subjects: 37
Study: 12383806

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT)‐trabeculectomy‐trabeculectomy (ATT) sequence
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Trabeculectomy‐ALT‐trabeculectomy (TAT) sequence
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: ATT sequence
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: TAT sequence
Number of subjects: 591
Study: 9527303

Group type: EXPERIMENTAL
Intervention: Randomized practices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Few practices randomized
Number of subjects: 0
Study: 8580280

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg q.d.s. for 1 week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ranitidine 300 mg t.d.s. for 1 week
Number of subjects: 20
Study: 1978070

Group type: EXPERIMENTAL
Intervention: Detection of serum and urinary aspergillus antigen
Number of subjects: 121
Study: 696787

Group type: EXPERIMENTAL
Intervention: Instruction by specially trained clinical teaching associates (professional patients and teachers)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group received practical instruction on office or clinic patients
Number of subjects: 100
Study: 31129370

Group type: EXPERIMENTAL
Intervention: Behavioral interventions aimed at improving glucose control
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Behavioral interventions aimed at optimizing use of diabetes devices
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Developmentally tailored behavioral supports with education
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sequential multiple assignment randomization trial (SMART) design
Number of subjects: 90
Study: 28637065

Group type: EXPERIMENTAL
Intervention: e-learning group
Number of subjects: 395

Group type: COMPARATOR
Intervention: non-e-learning group
Number of subjects: 395
Study: 25600619

Group type: EXPERIMENTAL
Intervention: Modified Marsh group
Number of subjects: 280

Group type: COMPARATOR
Intervention: Schnider group
Number of subjects: 280
Study: 23934002

Group type: EXPERIMENTAL
Intervention: Change Questionnaire (12-item instrument assessing motivation to change)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Change Questionnaire subscale 'Ability to change'
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Change Questionnaire overall score
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Change Questionnaire subscale 'Other change language dimensions'
Number of subjects: 213
Study: 21310080

Group type: EXPERIMENTAL
Intervention: Licorice flavonoid oil (LFO)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 20021675

Group type: EXPERIMENTAL
Intervention: dry‐needling, advice and exercise
Number of subjects: 120

Group type: COMPARATOR
Intervention: sham dry‐needling, advice and exercise
Number of subjects: 120
Study: 16739844

Group type: EXPERIMENTAL
Intervention: Governor Vessel Daoqi needling method combined with antidepressants
Number of subjects: 45

Group type: COMPARATOR
Intervention: Simple antidepressants
Number of subjects: 45
Study: 15193938

Group type: EXPERIMENTAL
Intervention: Visual paired comparison task (VPC)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Delayed matching to sample (DMS) task
Number of subjects: 1
Study: 10943230

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 9051333

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient preference for injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of oral and subcutaneous sumatriptan
Number of subjects: 0
Study: 8377981

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g single oral dose) for women and their partners
Number of subjects: 250

Group type: COMPARATOR
Intervention: Tinidazole (2 g single oral dose) for women
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo for male partners
Number of subjects: 250
Study: 3803198

Group type: EXPERIMENTAL
Intervention: Oral tilidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular tilidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meperidine, codeine, d-propoxyphene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral morphine
Number of subjects: 0
Study: 3384584

Group type: EXPERIMENTAL
Intervention: 2 x 200 mg dl‐alpha‐tocopheryl acetate
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31541495

Group type: EXPERIMENTAL
Intervention: HPV16/18 infection with borderline/low-grade cytology
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: HPV16/18 infection with normal cytology
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Other HPV types with borderline/low-grade cytology
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Other HPV types with normal cytology
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: New HPV infection in women with normal to low-grade cytology
Number of subjects: 379
Study: 28303587

Group type: EXPERIMENTAL
Intervention: AMX + 250 mg of MTZ for 14 days
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: AMX + 400 mg of MTZ for 14 days
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 250 or 400 mg of MTZ for 7 days
Number of subjects: 109

Group type: COMPARATOR
Intervention: SRP-only
Number of subjects: 109
Study: 26964159

Group type: EXPERIMENTAL
Intervention: Summer and winter acupuncture group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Non-summer and winter acupuncture group
Number of subjects: 240

Group type: COMPARATOR
Intervention: Western medication group (cetirizine)
Number of subjects: 240
Study: 23727881

Group type: EXPERIMENTAL
Intervention: Viewing neutral faces in a social task
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Viewing emotional expressions in a social task
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Viewing neutral faces
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Viewing emotional faces
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Social task
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gender task
Number of subjects: 21
Study: 21284065

Group type: EXPERIMENTAL
Intervention: Acceptance-based behavioral therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 31
Study: 19482866

Group type: EXPERIMENTAL
Intervention: Cladribine (5 mg/day for seven 5-day courses)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 84
Study: 16522140

Group type: EXPERIMENTAL
Intervention: Smaller object with static noise pattern
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Larger object with dynamic noise
Number of subjects: 0
Study: 12740678

Group type: EXPERIMENTAL
Intervention: Aceclofenac 2 x 100 mg daily
Number of subjects: 227

Group type: COMPARATOR
Intervention: Diclofenac resinate 2 x 75 mg daily
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Aceclofenac
Number of subjects: 227

Group type: COMPARATOR
Intervention: Diclofenac resinate
Number of subjects: 227
Study: 10699617

Group type: EXPERIMENTAL
Intervention: Prolonged combined androgen blockade (CAB) therapy (120 days or more)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Short-term combined androgen blockade (CAB) therapy (less than 120 days)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Prolonged CAB therapy (120 days or more) in patients who lived at least 2 years
Number of subjects: 813
Study: 9328500

Group type: EXPERIMENTAL
Intervention: Acamprosate 1332 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acamprosate 1998 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8229496

Group type: EXPERIMENTAL
Intervention: Bacterial polysaccharide immune globulin (BPIG), 0.5 ml/kg, administered intramuscularly at entry and 30 days later.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Saline placebo, administered intramuscularly at entry and 30 days later.
Number of subjects: 76
Study: 3096180

Group type: EXPERIMENTAL
Intervention: Esophageal perfusion of hydrochloric acid (HCl)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline (NaCl)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Esophageal perfusion of hydrochloric acid (HCl) in subjects with GER
Number of subjects: 12
Study: 29313180

Group type: COMPARATOR
Intervention: Pasireotide subcutaneous treatment (300–600 μg s.c. twice-daily)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pasireotide long-acting release (LAR) treatment (40–60 mg monthly)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pasireotide treatment overall
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pasireotide treatment
Number of subjects: 7
Study: 26708314

Group type: EXPERIMENTAL
Intervention: 150 mg aspirin daily for up to 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo daily for up to 24 weeks
Number of subjects: 0
Study: 25906770

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 60
Study: 23676420

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy after 4 months of chemotherapy
Number of subjects: 79

Group type: COMPARATOR
Intervention: Continuation of chemotherapy
Number of subjects: 79
Study: 19948082

Group type: EXPERIMENTAL
Intervention: Being mindset
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Becoming mindset
Number of subjects: 0
Study: 19040013

Group type: EXPERIMENTAL
Intervention: GIK intravenous infusion for 24 hours plus routine treatment (3739 patients)
Number of subjects: 7510

Group type: COMPARATOR
Intervention: Control group receiving routine treatment alone (3771 patients)
Number of subjects: 7510
Study: 16373887

Group type: EXPERIMENTAL
Intervention: Active titration with laboratory A1C testing
Number of subjects: 7893

Group type: EXPERIMENTAL
Intervention: Active titration with POC A1C testing
Number of subjects: 7893

Group type: COMPARATOR
Intervention: Usual titration with laboratory A1C testing
Number of subjects: 7893

Group type: COMPARATOR
Intervention: Usual titration with POC A1C testing
Number of subjects: 7893
Study: 12602372

Group type: EXPERIMENTAL
Intervention: Verteporfin + cold red laser therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo + cold red laser therapy
Number of subjects: 120
Study: 9929752

Group type: EXPERIMENTAL
Intervention: 4Fr diagnostic catheters
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5Fr diagnostic catheters
Number of subjects: 100
Study: 8672944

Group type: EXPERIMENTAL
Intervention: Compression stockings with 12 mmHg pressure
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Compression stockings with 20 mmHg pressure
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Compression stockings with 30 mmHg pressure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 80
Study: 2271125

Group type: EXPERIMENTAL
Intervention: ORS‐90 (60 mmol/L sodium, 90 mmol/L glucose, osmolality 311 mOsm/kg)
Number of subjects: 186

Group type: COMPARATOR
Intervention: ORS‐60 (60 mmol/L sodium, 90 mmol/L glucose, osmolality 240 mOsm/kg)
Number of subjects: 186
Study: 7282695

Group type: EXPERIMENTAL
Intervention: Follow-up telephone call (Group 2)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Written and oral consultation (Group 3)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Written and oral consultation plus call-back (Group 4)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Written and oral consultation
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Follow-up telephone call
Number of subjects: 82
Study: 29992904

Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 0

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 0
Study: 26562686

Group type: EXPERIMENTAL
Intervention: Episodic future thinking (EFT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control episodic recent thinking (ERT)
Number of subjects: 29
Study: 24445245

Group type: COMPARATOR
Intervention: Aripiprazole 1-15 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Aripiprazole 10-20 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Aripiprazole 15-28.1 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Aripiprazole 20-30 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Aripiprazole 10 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Aripiprazole <10 mg/day
Number of subjects: 22
Study: 22221492

Group type: EXPERIMENTAL
Intervention: Salmon
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Herring
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Pompano
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (meat mix)
Number of subjects: 126
Study: 20684264

Group type: EXPERIMENTAL
Intervention: New compound codonopsis tablets
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 17885563

Group type: EXPERIMENTAL
Intervention: Cilnidipine 10 mg once daily for 24 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily for 24 weeks
Number of subjects: 50
Study: 16036441

Group type: EXPERIMENTAL
Intervention: Step-by-step administration of the ROCF
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard administration of the ROCF
Number of subjects: 132
Study: 12142111

Group type: EXPERIMENTAL
Intervention: Biatrial pacing with leads sited at the high right atrium (HRA) and distal coronary sinus (DCS)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Right atrial (RA) pacing
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Coronary sinus (CS) pacing
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sequential pacing
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Simultaneous pacing
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 19
Study: 10186224

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer (repeated screening every third year for four rounds)
Number of subjects: 9169

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer
Number of subjects: 9169

Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 9169
Study: 7746765

Group type: EXPERIMENTAL
Intervention: Intensive educational interventions
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 2687558

Group type: EXPERIMENTAL
Intervention: Pharmorubicin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 30
Study: 29614982

Group type: EXPERIMENTAL
Intervention: Systematic focus on subtle changes during the check-in phase lasting from 7 to 20 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: State-of-the-art (SOTA) check-in phase lasting several minutes focused on session goals
Number of subjects: 0
Study: 28150955

Group type: EXPERIMENTAL
Intervention: Inpatient care for 21 days plus 6 months of continuing care
Number of subjects: 176

Group type: COMPARATOR
Intervention: Outpatient care for 21 days plus 6 months of continuing care
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Inpatient care
Number of subjects: 176
Study: 26652866

Group type: EXPERIMENTAL
Intervention: tools + basic training (Arm I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tools + enhanced training + facilitation (Arm II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propensity score-matched control group of clinics
Number of subjects: 0
Study: 23522245

Group type: EXPERIMENTAL
Intervention: Self-management of blood pressure (BP)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 540
Study: 22083986

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AAG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal control group (NCG)
Number of subjects: 24
Study: 19808133

Group type: EXPERIMENTAL
Intervention: ALN monohydrate 10 mg once daily for 12 weeks
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 438
Study: 16460246

Group type: EXPERIMENTAL
Intervention: Subgingival instrumentation using PVP-I (10%) as the cooling liquid
Number of subjects: 44

Group type: COMPARATOR
Intervention: Identical treatment using distilled water as the cooling liquid (control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 15255451

Group type: EXPERIMENTAL
Intervention: Multivitamin-trace element supplement
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo containing calcium
Number of subjects: 44
Study: 11261333

Group type: EXPERIMENTAL
Intervention: Optimized uni‐ or biventricular pacing therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional right ventricular stimulation
Number of subjects: 50